Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hypertension Management

Background:

• Central blood pressure (CBP) and pulse wave velocity (PWV) are key indicators in managing hypertension.
• Elevated PWV correlates with arterial stiffness, and CBP predicts cardiovascular outcomes better than peripheral pressure.
• Reducing CBP offers protection against subclinical organ damage.

Purpose of the Study:

• To evaluate the efficacy of Amlodipine/Nebivolol (A/N) in reducing central blood pressure (CBP), peripheral blood pressure (PBP), and PWV.
• To compare the effects of A/N with the established Amlodipine/Valsartan (A/V) combination therapy.

Main Methods:

• A randomized controlled trial involving 102 hypertensive patients from October 2018 to August 2020.
• Patients were assigned to either Amlodipine 10 mg/Nebivolol 5 mg (A/N, n=50) or Amlodipine 10 mg/Valsartan 160 mg (A/V, n=52).
• Office BP, CBP, and PWV were measured at baseline, 4-8 weeks, and 10-12 weeks.

Main Results:

• No significant differences in baseline characteristics (age, gender, BMI, CV history) between the A/V and A/N groups.
• Both A/V and A/N therapies significantly reduced OBP, CBP, and PWV within their respective groups.
• No statistically significant differences in BP or PWV reduction were observed when comparing the A/N and A/V groups.

Conclusions:

• Amlodipine/Nebivolol (A/N) combination therapy effectively reduces central blood pressure, peripheral blood pressure, and pulse wave velocity.
• The A/N combination demonstrated comparable efficacy to Amlodipine/Valsartan (A/V) therapy.
• A/N exhibited minor and tolerable side effects, suggesting its potential as a viable treatment option.